| P/E (FY) | 79.4 | Sales (TTM) | — |
| Earnings (TTM) | -$31.3M | ROE | −69.54% |
| Net Margin | — | ROIC | −1446.22% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | −47.01% | Sales Growth 3Y | — |
| Market Cap | $822.8M | Trading Days | 1341 |
| 52W High | 4.80 |
| 52W Low | 1.35 |
| % Off High | −70.21% |
| YTD | −13.33% | 1Y | −67.20% |
| 3Y | −72.50% | 5Y | −97.84% |
| Since incept. (ann.) | −59.72% |
| Ann. Volatility (1Y) | 88.26% | Ann. Volatility (3Y) | 89.16% |
| Sharpe (1Y) | −0.85 | Sharpe (3Y) | −0.05 |
| Max Drawdown (1Y) | −68.81% | Max Drawdown (3Y) | −86.18% |
| Beta (3Y, vs SPY) | 1.90 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| KURA | Kura Oncology, Inc. | $826.5M | — |
| ESPR | Esperion Therapeutics, Inc. | $818.6M | — |
| OMER | OMEROS CORP | $816.4M | — |
| TBPH | Theravance Biopharma, Inc. | $870.7M | 8.2 |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| ANNX | Annexon, Inc. | $770.9M | — |
| CYRX | Cryoport, Inc. | $764.6M | 10.8 |
| AMPH | Amphastar Pharmaceuticals, Inc. | $888.5M | 9.9 |
| ACRS | Aclaris Therapeutics, Inc. | $744.4M | — |
| DSGN | Design Therapeutics, Inc. | $741.4M | — |
| JANX | Janux Therapeutics, Inc. | $914.8M | — |
| MNPR | Monopar Therapeutics | $730.8M | — |
